Phase 3 Recruiting Academic/Other
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Vermont:
- Central Vermont Medical Center/National Life Cancer Treatment — Berlin Corners, Vermont
- University of Vermont Medical Center — Burlington, Vermont
- University of Vermont and State Agricultural College — Burlington, Vermont
- Dartmouth Cancer Center - North — Saint Johnsbury, Vermont